Phillip R. Muskin, MD, discusses the complexities of prescribing antipsychotics, emphasizing patient collaboration and the importance of evaluating treatment strategies.
Talking With Titans
Take a look at innovative GSK-3β inhibitors to enhance efficacy and reduce adverse effects seen in lithium with Jonathan M. Meyer, MD, DLFAPA, at the 2025 APA Annual Meeting.
Advertisement
Discover how insulin influences mood and cognition, revealing new therapeutic possibilities for depression and bipolar disorder, in this discussion with Roger McIntyre, MD, FRCPC, at the 2025 APA Annual Meeting.
A Shift in the Way We Think About the Biology of Depression: A Conversation With John H. Krystal, MD
Experts discuss groundbreaking insights on ketamine's role in treating depression, highlighting its rapid effects and potential to transform psychopharmacology.
How does adult ADHD differ from pediatric ADHD? Jeffrey Newcorn, MD, shared his expertise at the 2025 APA Annual Meeting.
Antipsychotic plasma levels play a critical role of in treatment decisions. Learn more in this conversation from the 2025 APA Annual Meeting.
Advertisement
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Accepts NDA for CTx-1301 for Treatment of ADHD
2
New Data on Lumateperone for Prevention of Relapse in Schizophrenia
3
Exploring CBT Approaches for Chronic Insomnia in Adults: A Systematic Review and Network Meta-Analysis
4
Medical Morality vs Chatbot Morality
5
